Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
12
02
2024
accepted:
17
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The 2023 nomenclature defined criteria for steatotic liver disease (SLD), including metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and the overlapping MASLD/ALD (MetALD). We aimed to assess racial and ethnic disparities in the SLD prevalence among United States (US) adults based on this new nomenclature. We undertook a cross-sectional study employing the 2017-2018 National Health and Nutrition Examination Survey (NHANES) database. We identified SLD according to a controlled attenuation parameter ≥288 dB/m, liver stiffness ≥7.2 kPa, or elevated aminotransferase levels. Alcohol use thresholds were established according to the updated SLD definition. We estimated prevalences using the complex design of the NHANES survey. Multivariable logistic regressions with complex design weights were employed. A total of 5532 individuals are included. The mean age is 45.4 years, and 50.9% are women. The adjusted estimated prevalence of MASLD is 42.4% (95% CI: 41.1-43.8%), MetALD 1.7% (95% CI: 1.3-2.0%), and ALD 0.6% (95% CI: 0.3-0.8%). Hispanics exhibit a higher prevalence of SLD, but there are no significant differences in advanced fibrosis prevalence due to SLD among racial/ethnic groups. In MASLD, men, individuals aged 40-64 and ≥65 years, Hispanics, those with health insurance, higher BMI, diabetes, hypertension, hypertriglyceridemia, and low high-density lipoprotein (HDL) cholesterol or use of lipid-lowering agents are independently associated with a higher risk, while Blacks have the lowest risk. In MetALD, men and higher BMI are independently associated with a higher risk of MetALD in adjusted multivariable analysis. In ALD, the adjusted multivariable analysis shows that only health insurance is independently associated with a lower ALD risk. MASLD prevalence is high in the US, especially in men, older individuals, and Hispanics. MetALD and ALD prevalence was substantial but could be underestimated. This study aims to estimate the prevalence of different types of fatty liver disease, in which excess fat occurs in the liver. A particular type of fatty liver disease that is not caused by excess alcohol consumption affects 42.4% of adults in the USA, with men, older adults, and Hispanics being more likely to have this form of liver disease. People with health insurance are less likely to have liver disease caused by excess alcohol consumption. These results highlight the importance of targeted prevention efforts in people with a higher risk of developing liver disease. Future public health strategies should focus on reducing risk factors and providing equitable healthcare access.
Autres résumés
Type: plain-language-summary
(eng)
This study aims to estimate the prevalence of different types of fatty liver disease, in which excess fat occurs in the liver. A particular type of fatty liver disease that is not caused by excess alcohol consumption affects 42.4% of adults in the USA, with men, older adults, and Hispanics being more likely to have this form of liver disease. People with health insurance are less likely to have liver disease caused by excess alcohol consumption. These results highlight the importance of targeted prevention efforts in people with a higher risk of developing liver disease. Future public health strategies should focus on reducing risk factors and providing equitable healthcare access.
Identifiants
pubmed: 39472739
doi: 10.1038/s43856-024-00649-x
pii: 10.1038/s43856-024-00649-x
doi:
Types de publication
Journal Article
Langues
eng
Pagination
219Informations de copyright
© 2024. The Author(s).
Références
Younossi, Z. M., Wong, G., Anstee, Q. M. & Henry, L. The global burden of liver disease. Clin. Gastroenterol. Hepatol. 21, 1978–1991 (2023).
doi: 10.1016/j.cgh.2023.04.015
pubmed: 37121527
Díaz, L. A. et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol. Hepatol. https://doi.org/10.1016/S2468-1253(22)00008-5 (2022).
En Li Cho, E. et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72, 2138–2148 (2023).
doi: 10.1136/gutjnl-2023-330110
pubmed: 37491159
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R. & Arrese, M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-023-00822-y (2023).
Kim, H.-S. et al. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open 5, e2234221 (2022).
doi: 10.1001/jamanetworkopen.2022.34221
pubmed: 36190732
pmcid: 9530967
Díaz, L. A. et al. Liver diseases in Latin America: current status, unmet needs, and opportunities for improvement. Curr. Treat. Options Gastroenterol. 20, 261–278 (2022).
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology https://doi.org/10.1097/HEP.0000000000000520 (2023).
Lee, B. P., Dodge, J. L. & Terrault, N. A. National prevalence estimates for steatotic liver disease and sub-classifications using consensus nomenclature. Hepatology https://doi.org/10.1097/HEP.0000000000000604 (2023).
Ciardullo, S., Carbone, M., Invernizzi, P. & Perseghin, G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 43, 2425–2433 (2023).
doi: 10.1111/liv.15695
pubmed: 37592856
Kalligeros, M. et al. Prevalence of steatotic liver disease (MASLD, MetALD and ALD) in the United States: NHANES 2017-2020. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2023.11.003 (2023).
Perazzo, H., Pacheco, A. G., Griep, R. H. & Collaborators. Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.08.025 (2023).
Cotter, T. G. et al. Racial and ethnic disparities in liver transplantation for alcohol-associated liver diseases in the United States. Transplantation https://doi.org/10.1097/TP.0000000000004701 (2023).
Anouti, A. et al. Racial and ethnic disparities in alcohol-associated liver disease in the United States: a systematic review and meta-analysis. Hepatol. Commun. 8, e0409 (2024).
Ayares, G. et al. Racial and ethnic disparities in the natural history of alcohol-associated liver disease in the United States. Liver Int. https://doi.org/10.1111/liv.16023 (2024).
Rich, N. E. et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 16, 198–210.e2 (2018).
doi: 10.1016/j.cgh.2017.09.041
pubmed: 28970148
Singal, A. K. et al. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment. Pharmacol. Ther. 54, 451–461 (2021).
doi: 10.1111/apt.16461
pubmed: 34247424
Caussy, C. et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 67, 1348–1359 (2018).
doi: 10.1002/hep.29639
pubmed: 29108123
Foucher, J. et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55, 403–408 (2006).
doi: 10.1136/gut.2005.069153
pubmed: 16020491
pmcid: 1856085
Wong, T., Dang, K., Ladhani, S., Singal, A. K. & Wong, R. J. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. JAMA 321, 1723–1725 (2019).
doi: 10.1001/jama.2019.2276
pubmed: 31063562
pmcid: 6506872
Degertekin, B. et al. Determination of the upper limits of normal serum alanine aminotransferase (ALT) level in healthy Turkish population. Hepatol. Forum 1, 44–47 (2020).
pubmed: 35949438
pmcid: 9349345
Lee, J. K. et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51, 1577–1583 (2010).
doi: 10.1002/hep.23505
pubmed: 20162730
Chang, Y., Ryu, S., Sung, E. & Jang, Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin. Chem. 53, 686–692 (2007).
doi: 10.1373/clinchem.2006.081257
pubmed: 17272484
Eddowes, P. J. et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1717–1730 (2019).
doi: 10.1053/j.gastro.2019.01.042
pubmed: 30689971
Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362–373 (2020).
doi: 10.1016/S2468-1253(19)30383-8
pubmed: 32027858
pmcid: 7066580
Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598–1606 (2022).
doi: 10.1016/j.jhep.2022.08.021
pubmed: 36208844
pmcid: 9670241
Duell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 42, e168–e185 (2022).
doi: 10.1161/ATV.0000000000000153
pubmed: 35418240
Setiawan, V. W. et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology 64, 1969–1977 (2016).
doi: 10.1002/hep.28677
pubmed: 27301913
Kallwitz, E. R. et al. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin. Gastroenterol. Hepatol. 13, 569–576 (2015).
doi: 10.1016/j.cgh.2014.08.037
pubmed: 25218670
Rieman-Klingler, M. C., Jung, J., Tesfai, K., Loomba, R. & Non, A. L. Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease. Am. J. Biol. Anthropol. 184, e24979 (2024).
Wang, J. et al. Association of genetic risk score with NAFLD in an ethnically diverse cohort. Hepatol. Commun. 5, 1689–1703 (2021).
doi: 10.1002/hep4.1751
pubmed: 34558842
pmcid: 8485887
Pinto Marques Souza de Oliveira, C., Pinchemel Cotrim, H. & Arrese, M. Nonalcoholic fatty liver disease risk factors in Latin American populations: current scenario and perspectives. Clin. Liver Dis. 13, 39–42 (2019).
doi: 10.1002/cld.759
Pontoriero, A. C. et al. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genet. 16, 93 (2015).
doi: 10.1186/s12863-015-0255-3
pubmed: 26219465
pmcid: 4518515
Vidal, T. M., Williams, C. A., Ramoutar, U. D. & Haffizulla, F. Type 2 diabetes mellitus in Latinx populations in the United States: a culturally relevant literature review. Cureus 14, e23173 (2022).
pubmed: 35444916
pmcid: 9009996
Mora, N. & Golden, S. H. Understanding cultural influences on dietary habits in Asian, Middle Eastern, and Latino patients with type 2 diabetes: a review of current literature and future directions. Curr. Diab. Rep. 17, 126 (2017).
doi: 10.1007/s11892-017-0952-6
pubmed: 29063419
Kardashian, A., Dodge, J. L. & Terrault, N. A. Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population-based study. Aliment. Pharmacol. Ther. 56, 1383–1393 (2022).
doi: 10.1111/apt.17219
pubmed: 36173037
pmcid: 9828576
Saab, S., Manne, V., Nieto, J., Schwimmer, J. B. & Chalasani, N. P. Nonalcoholic fatty liver disease in Latinos. Clin. Gastroenterol. Hepatol. 14, 5–12 (2016).
doi: 10.1016/j.cgh.2015.05.001
pubmed: 25976180
Wagenknecht, L. E. et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int. 31, 412–416 (2011).
doi: 10.1111/j.1478-3231.2010.02444.x
pubmed: 21281435
pmcid: 3703938
Boersma, P., Black, L. I. & Ward, B. W. Prevalence of multiple chronic conditions among US Adults, 2018. Prev. Chronic Dis. 17, E106 (2020).
doi: 10.5888/pcd17.200130
pubmed: 32945769
pmcid: 7553211
Probst, C., Kilian, C., Sanchez, S., Lange, S. & Rehm, J. The role of alcohol use and drinking patterns in socioeconomic inequalities in mortality: a systematic review. Lancet Public Health 5, e324–e332 (2020).
doi: 10.1016/S2468-2667(20)30052-9
pubmed: 32504585
Chartier, K. & Caetano, R. Ethnicity and health disparities in alcohol research. Alcohol Res. Health 33, 152–160 (2010).
pubmed: 21209793
pmcid: 3887493
Vaeth, P. A. C., Wang-Schweig, M. & Caetano, R. Drinking, alcohol use disorder, and treatment access and utilization among U.S. racial/ethnic groups. Alcohol. Clin. Exp. Res. 41, 6–19 (2017).
doi: 10.1111/acer.13285
pubmed: 28019654
Castañeda, S. F. et al. Alcohol use, acculturation and socioeconomic status among Hispanic/Latino men and women: The Hispanic Community Health Study/Study of Latinos. PLoS One 14, e0214906 (2019).
doi: 10.1371/journal.pone.0214906
pubmed: 30947280
pmcid: 6449031
Grant, B. F. et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 74, 911–923 (2017).
doi: 10.1001/jamapsychiatry.2017.2161
pubmed: 28793133
pmcid: 5710229
Vannier, A. G. L. et al. Incidence and progression of alcohol-associated liver disease after medical therapy for Alcohol Use Disorder. JAMA Netw Open 5, e2213014 (2022).
doi: 10.1001/jamanetworkopen.2022.13014
pubmed: 35594048
pmcid: 9123494
Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.04.040 . (2022)
Liu, B., Balkwill, A., Reeves, G., Beral, V. & Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ 340, c912 (2010).
doi: 10.1136/bmj.c912
pubmed: 20223875
pmcid: 2837146
Åberg, F., Helenius-Hietala, J., Puukka, P., Färkkilä, M. & Jula, A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 67, 2141–2149 (2018).
doi: 10.1002/hep.29631
pubmed: 29164643
Decraecker, M. et al. Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. Liver Int. 42, 350–362 (2022).
doi: 10.1111/liv.15081
pubmed: 34679242
Israelsen, M., Torp, N., Johansen, S., Thiele, M. & Krag, A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol. Hepatol. 8, 866–868 (2023).
doi: 10.1016/S2468-1253(23)00206-6
pubmed: 37567208
Díaz, L. A. et al. Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multinational study. Hepatology 74, 2478–2490 (2021).
doi: 10.1002/hep.32016
pubmed: 34134172
Díaz, L. A. et al. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.11.006 . (2023)
Lazarus, J. V. et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J. Hepatol. 76, 771–780 (2022).
doi: 10.1016/j.jhep.2021.10.025
pubmed: 34895743
Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60–78 (2022).
doi: 10.1038/s41575-021-00523-4
pubmed: 34707258
Lazarus, J. V. et al. A global research priority agenda to advance public health responses to fatty liver disease. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.04.035 (2023).
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M. R. & Lazarus, J. V. Envisioning how to advance the MASH field. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-024-00938-9 (2024).
Danpanichkul, P., Suparan, K., Kim, D. & Wijarnpreecha, K. What is new in metabolic dysfunction-associated steatotic liver disease in lean individuals: from bench to bedside. J. Clin. Med. 13, 278 (2024).